| Balance Sheets | 2026-06-30 | |||
|---|---|---|---|---|
| Cash and cash equivalents | 26,903 | |||
| Marketable securities | 159,538 | |||
| Prepaid expenses | 1,359 | |||
| Other current assets | 858 | |||
| Total current assets | 188,658 | |||
| Right of use assets - operating leases, net | 524 | |||
| Right of use assets - financing leases, net | 0 | |||
| Total property and equipment | 650 | |||
| Less accumulated depreciation and amortization | 606 | |||
| Property and equipment, net | 44 | |||
| Other non-current assets | 80 | |||
| Total assets | 189,306 | |||
| Accounts payable and accrued expenses | 7,573 | |||
| Compensation and employee benefits liabilities | 1,415 | |||
| Operating lease liabilities, current | 592 | |||
| Financing lease liabilities, current | 0 | |||
| Total current liabilities | 9,580 | |||
| Operating lease liabilities, non-current | 0 | |||
| Other non-current liabilities | 1 | |||
| Total liabilities | 9,581 | |||
| Series b redeemable convertible preferred stock, 0.0001 par value 502 and zero shares authorized as of june 30, 2026 and december 31, 2025, respectively 502 and zero shares issued and outstanding as of june 30, 2026, and december 31, 2025, respectively liquidation value of 0 as of june 30, 2026 | 6,767 | |||
| Common stock, 0.0001 par value 300,000,000 shares authorized as of june 30, 2026 and 12,500,000 shares authorized as of december 31, 2025 25,832,969 and 1,261,685 shares issued and outstanding as of june 30, 2026 and december 31, 2025, respectively | 2 | |||
| Additional paid-in capital | 642,399 | |||
| Accumulated deficit | -469,380 | |||
| Accumulated other comprehensive (loss) income | -63 | |||
| Total stockholders' equity | 172,958 | |||
| Total liabilities, redeemable convertible preferred stock, and stockholders' equity | 189,306 | |||
Faeth Therapeutics, Inc. (FTH)
Faeth Therapeutics, Inc. (FTH)